Pfizer Abrilada, biosimilar to Humira gets USFDA nod for multiple inflammatory conditions Farhat Nasim20 Nov 2019 12:44 PM ISTNew Delhi: Pfizer Inc. recently announced the United States (U.S.) Food and Drug Administration (USFDA) has approved ABRILADA (adalimumab-afzb), as a...
Novartis gets U.S. nod for long-delayed copycat version of Amgen billion seller Neulasta drug Medical Dialogues Bureau6 Nov 2019 10:32 AM ISTZURICH: Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in...
Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals Medical Dialogues Bureau3 Sept 2019 9:30 AM ISTNovartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of...
Pfizer gets USFDA nod for biosimilar to Rituximab Medical Dialogues Bureau25 July 2019 8:59 AM ISTRuxience is a mAb biosimilar to Rituxan which works by targeting a protein called CD20, which is present on the surface of B cells. Ruxience is...
Novartis CEO sets aside 700 Million Dollar to settle doctor bribery lawsuit Medical Dialogues Bureau20 July 2019 9:52 AM ISTZURICH: Novartis Chief Executive Vas Narasimhan set aside $700 million to settle a U.S. doctor bribery lawsuit, as the Swiss drugmaker seeks to close...
Dr Reddys plans to launch value-added drugs in US as part of diversification, market entry strategy Medical Dialogues Bureau8 July 2019 1:32 PM ISTAs part of the diversification and new market entry strategy, DRL (Dr Reddys) plans to re-focus some of its Research and Development resources to...
Biocon, Mylan gets Canadian nod for biosimilar of cancer drug Herceptin Farhat Nasim23 May 2019 11:59 AM ISTOgivri is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Biocon and Mylan's joint portfolio approved in the...
Biocon commercial rights on biosimilar adalimumab extends to global markets Farhat Nasim8 May 2019 9:45 AM ISTBiocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing...
Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate Meghna A Singhania11 April 2019 10:50 AM ISTMumbai: In a move that will provide relief to cancer patients, drugmaker Intas Pharmaceuticals has recently announced the launch of Trastuzumab...
Novartis division resubmits USFDA application for biosimilar Pegfilgrastim Farhat Nasim4 April 2019 9:15 AM ISTNew Delhi: Novartis division, Sandoz, recently announced resubmission of its Biologics License Application (BLA) for a proposed biosimilar...
USFDA approves Mylan, Biocon's Fulphila, the first biosimilar to Neulasta Ruby Khatun Khatun6 Jun 2018 10:30 AM ISTHERTFORDSHIRE/PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's...
Biocon, Mylan get European Commission approval to market biosimilar insulin glargine Ruby Khatun Khatun30 March 2018 10:30 AM ISTNew Delhi: Biotechnology major Biocon and Mylan said their co-developed biosimilar insulin glargine has received marketing authorization approval from...
